Qiang Zhao
Director/Board Member chez Shanghai Haihe Biopharma Co., Ltd.
Profil
Qiang Zhao is an Independent Director at Shanghai Haihe Biopharma Co., Ltd.
since 2020.
Prior to this, he held the position of Independent Director at Jionto Energy Investment Co., Ltd.
Hebei.
He also served as an Independent Director at Beijing Chieftain Control Engineering Technology Co., Ltd.
from 2017 to 2023.
Postes actifs de Qiang Zhao
| Sociétés | Poste | Début |
|---|---|---|
Shanghai Haihe Biopharma Co., Ltd.
 Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Director/Board Member | 08/09/2020 |
Anciens postes connus de Qiang Zhao
| Sociétés | Poste | Fin |
|---|---|---|
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Director/Board Member | 10/06/2023 |
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Utilities |
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Producer Manufacturing |
| Entreprise privées | 1 |
|---|---|
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Commercial Services |
